|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
Potential intravenous tissue plasminogen activator candidates experienced the shortest time to neuroimaging after implementation of a stroke alert system (54 minutes; IQR, 34-66 minutes [n = 13] for intravenous tissue plasminogen activator candidates vs 89.5 minutes; IQR, 62-126.5 minutes [n = 52] for non-intravenous tissue plasminogen activator candidates; P < .01).
|
31704052 |
2020 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
Following the results of randomized clinical trials supporting the use of mechanical thrombectomy (MT) with tissue plasminogen activator for emergent large vessel occlusion (ELVO), our state Stroke Task Force convened to: update legislation to recognize differences between Primary Stroke Centers (PSCs) and Comprehensive Stroke Centers (CSCs); and update Emergency Medical Services (EMS) protocols to triage direct transport of suspected ELVO patients to CSCs.
|
30530770 |
2020 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
The aim of this study was to prospectively investigate the occurrence of early poststroke seizures (within 7 days of stroke) in patients undergoing reperfusion therapies (intravenous rtPA [recombinant tissue plasminogen activator] and/or endovascular thrombectomy) in comparison to those not undergoing these procedures.
|
31431399 |
2020 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
The Effect of Clot Volume and Permeability on Response to Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke.
|
31810719 |
2020 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
The only way of managing patients with ischemic stroke is the use of intravenous tissue plasminogen activator and endovascular thrombectomy.
|
31612315 |
2020 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Intravenous recombinant tissue plasminogen activator is considered for acute ischemic stroke.
|
31623507 |
2020 |
|
C20orf181
|
Ischemic stroke
|
0.100 |
Biomarker |
BEFREE |
Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-β1 for treating ischemic stroke using tissue plasminogen activator.
|
31478148 |
2020 |
|
C20orf181
|
Cerebral Infarction
|
0.100 |
Biomarker |
BEFREE |
He was diagnosed with acute cerebral infarction and was administered with tissue plasminogen activator.
|
30527791 |
2019 |
|
C20orf181
|
Cerebral Infarction
|
0.100 |
Biomarker |
BEFREE |
Tissue plasminogen activator disrupts the blood-brain barrier through increasing the inflammatory response mediated by pericytes after cerebral ischemia.
|
31740626 |
2019 |
|
C20orf181
|
Cerebral Infarction
|
0.100 |
Biomarker |
BEFREE |
Prothymosin alpha and its mimetic hexapeptide improve delayed tissue plasminogen activator-induced brain damage following cerebral ischemia.
|
31454420 |
2019 |
|
C20orf181
|
Cerebral Infarction
|
0.100 |
Biomarker |
BEFREE |
Here, we determined whether tPA could damage brain microvascular endothelial cells (BMECs) during cerebral ischemia.
|
30552546 |
2019 |
|
C20orf181
|
Myocardial Infarction
|
0.100 |
AlteredExpression |
BEFREE |
Upregulation in the fibrosis signaling cascade proteins such as fibroblast growth factor (FGF), urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and activation of matrix metalloproteinases (MMPs) are widely associated with the development of myocardial infarction, dilated cardiomyopathy, cardiac fibrosis and heart failure.
|
30980805 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
Methods- NINDS rt-PA Study (National Institute for Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator) and SWIFT PRIME trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment) patients were matched for prognosis (based on age and National Institutes of Health Stroke Scale) and definite/likely anterior circulation large vessel occlusion (based on National Institutes of Health Stroke Scale total score and item pattern), using optimal inverse variance matching, to determine comparative outcomes with nonreperfusion care alone, IVT alone, and IVT+EVT.
|
31311465 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
Tissue plasminogen activator is the only U.S. FDA-approved therapy for ischemic stroke, while there is no specific medication for hemorrhagic stroke.
|
30775405 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
We further found that the expression of Arg-1 was also upregulated in those tPA and RSG-treated stroke mice and the protection against tPA-induced HT and BBB disruption in these mice were abolished in the presence of PPAR-γ antagonist GW9662 (4 mg/kg, 1 hour before dMCAO through intraperitoneal injection).
|
31756041 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
One developed an ICH after receiving tissue plasminogen activator for a cerebrovascular accident after two negative CTs.
|
30336936 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
GeneticVariation |
BEFREE |
Black individuals and Hispanic individuals are less likely to recognize stroke and call 911 (stroke preparedness), contributing to racial/ethnic disparities in intravenous tissue plasminogen activator use.
|
31260028 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
Minimally invasive surgery procedures, including stereotactic catheter aspiration and clearance of intracerebral hemorrhage (ICH) with recombinant tissue plasminogen activator hold a promise to improve outcome of supratentorial brain hemorrhage, a morbid and disabling type of stroke.
|
30891610 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
Stroke is one of the leading causes of death and disability globally, while intravenous thrombolysis with recombinant tissue plasminogen activator remains the only Food and Drug Administration (FDA)-approved therapy for ischemic stroke.
|
30404981 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
These improvements in outcomes were most strongly associated with process interventions that allocate stroke-specific physical and human resources in the ED, most notably a designated emergency room space for stroke, and with workflows that decrease the time to key checkpoints for determining a patient's eligibility for tPA.
|
31230040 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
The patient was not a candidate for intravenous tissue plasminogen activator because he presented with a wake-up stroke.
|
30060127 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
Although the sample size was small, this study also illustrates the lack of clear efficacy data for optimal treatment strategies, and the ongoing treatment challenges in posterior circulation stroke population in a population of patients outside the rt-PA window.
|
31807387 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
We describe 2 cases of patients with stroke after TAVI who received tPA therapy and mechanical thrombectomy.
|
31327683 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
Awareness of the typical findings, pearls, and pitfalls of CT image interpretation is therefore critical for radiologists, stroke neurologists, and emergency department providers to make accurate and timely decisions regarding both <i>(a)</i> immediate treatment with intravenous tissue plasminogen activator up to 4.5 hours after a stroke at primary stroke centers and <i>(b)</i> transfer of patients with large-vessel occlusion (LVO) at CT angiography to comprehensive stroke centers for endovascular thrombectomy (EVT) up to 24 hours after a stroke.
|
31589578 |
2019 |
|
C20orf181
|
Cerebrovascular accident
|
0.100 |
Biomarker |
BEFREE |
Cumulative 3-year incidences of the co-primary bleeding end points of intracranial hemorrhage, non-intracranial global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO) moderate/severe bleeding, and the primary ischemic end point of ischemic stroke/myocardial infarction were higher in the prior hemorrhagic and ischemic stroke groups than in the no-prior stroke group (6.8%, 2.5%, and 1.3%, <i>P</i><0.0001, 8.8%, 8.0%, and 6.0%, <i>P</i>=0.001, and 12.7%, 13.4%, and 7.5%, <i>P</i><0.0001).
|
31701821 |
2019 |